Published in Medical Verdicts and Law Weekly, June 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at BioMarin Pharmaceutical Inc..
Report 1: BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced that it intends to offer to sell, subject to market and other conditions, $250 million aggregate principal amount of senior subordinated convertible notes due 2017 in an underwritten public offering. The Company intends to grant the underwriters a 13-day option to purchase up to an additional $37.5 million of notes to cover over-allotments.
Merrill Lynch & Co....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.